Mereo BioPharma Group plc

Pharmaceutical company · London, England, United Kingdom · Nasdaq: MREO

Mereo BioPharma Group plc is a pharmaceutical company headquartered in London, England, United Kingdom. Its earliest recorded incorporation is in 2015. Its shares trade on Nasdaq under the ticker MREO. It has reported private securities offerings to the US SEC, most recently $70 million sold in a notice filed in 2020. It is registered with UK Companies House under company number 09481161.

Profile compiled from public records. Is this your company? Request a correction or update

Mereo BioPharma Group at a glance

Typepharmaceutical company
HeadquartersLondon, England, United Kingdom
Earliest incorporation on record2015
Stock listingNasdaq: MREO
SEC industryPharmaceutical Preparations
Registered activities (UK)Research and experimental development on biotechnology
UK company number09481161
SEC CIK1719714

What does Mereo BioPharma Group do?

Private fundraising reported to the SEC

1 Form D notice; the most recent reported $70 million sold (2020).

Frequently asked questions about Mereo BioPharma Group

Where is Mereo BioPharma Group headquartered?

Mereo BioPharma Group plc is headquartered in London, England, United Kingdom.

What does Mereo BioPharma Group do?

Mereo BioPharma Group plc is a pharmaceutical company. Its SEC industry classification is Pharmaceutical Preparations.

Is Mereo BioPharma Group a public company?

Yes. Mereo BioPharma Group plc trades on Nasdaq under the ticker MREO.

When was Mereo BioPharma Group founded?

The earliest incorporation on record for Mereo BioPharma Group plc is in 2015, according to public company registers.

Similar companies

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Sources

Contains public sector information licensed under the Open Government Licence v3.0 (UK Companies House).

Location data: GeoNames (geonames.org), CC BY 4.0.

Last updated 2026-09-23.